FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972912578> ?p ?o ?g. }

• W1972912578 endingPage "768" @default.
• W1972912578 startingPage "760" @default.
• W1972912578 abstract "Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the addition of aflibercept to docetaxel and prednisone would improve overall survival in men with metastatic castrate-resistant prostate cancer compared with the addition of placebo to docetaxel and prednisone.VENICE was a phase 3, multicentre, randomised double-blind placebo-controlled parallel group study done in 31 countries (187 sites). Men with metastatic castrate-resistant prostate cancer, adequate organ function, and no prior chemotherapy were treated with docetaxel (75 mg/m(2) intravenously every 3 weeks) and oral prednisone (5 mg twice daily) and randomly allocated (1:1) to receive aflibercept (6 mg/kg) or placebo, intravenously, every 3 weeks. Treatment allocation was done centrally via an interactive voice response system, using a computer-generated sequence with a permuted-block size of four and stratified according Eastern Co-operative Group performance status (0-1 vs 2). Patients, investigators, and other individuals responsible for study conduct and data analysis were masked to treatment assignment. Aflibercept or placebo vials were supplied in identical boxes. The primary endpoint was overall survival using intention-to-treat analysis. This is the primary analysis of the completed trial. The study is registered with ClinicalTrials.gov, number NCT00519285 FINDINGS: Between Aug 17, 2007, and Feb 11, 2010, 1224 men were randomly allocated to treatment: 612 to each group. At final analysis, median follow-up was 35 months (IQR 29-41) and 873 men had died. Median overall survival was 22·1 months (95·6% CI 20·3-24·1) in the aflibercept group and 21·2 months (19·6-23·8) in the placebo group (stratified hazard ratio 0·94, 95·6% CI 0·82-1·08; p=0·38). We recorded a higher incidence of grade 3-4 gastrointestinal disorders (182 [30%] vs 48 [8·0%]), haemorrhagic events (32 [5·2%] vs ten [1·7%]), hypertension (81 [13%] vs 20 [3·3%]), fatigue (97 [16%] vs 46 [7·7%]), infections (123 [20%] vs 60 [10%]) and treatment-related fatal adverse events (21 [3·4%] vs nine [1·5%]) in the aflibercept group than in the placebo group.Aflibercept in combination with docetaxel and prednisone given as first-line chemotherapy for men with metastatic castrate-resistant prostate cancer resulted in no improvement in overall survival and added toxicity compared with placebo. Docetaxel plus prednisone remains the standard treatment for such men who need first-line chemotherapy.Sanofi and Regeneron Pharmaceuticals Inc." @default.
• W1972912578 created "2016-06-24" @default.
• W1972912578 creator A5001456598 @default.
• W1972912578 creator A5007779528 @default.
• W1972912578 creator A5008067367 @default.
• W1972912578 creator A5013626155 @default.
• W1972912578 creator A5018358609 @default.
• W1972912578 creator A5028324203 @default.
• W1972912578 creator A5028926236 @default.
• W1972912578 creator A5034896538 @default.
• W1972912578 creator A5041215843 @default.
• W1972912578 creator A5046813012 @default.
• W1972912578 creator A5056263585 @default.
• W1972912578 creator A5064387281 @default.
• W1972912578 creator A5067036952 @default.
• W1972912578 creator A5072043188 @default.
• W1972912578 creator A5073295040 @default.
• W1972912578 creator A5076098983 @default.
• W1972912578 creator A5078851457 @default.
• W1972912578 creator A5080433169 @default.
• W1972912578 creator A5083604333 @default.
• W1972912578 creator A5086158535 @default.
• W1972912578 creator A5089060647 @default.
• W1972912578 date "2013-07-01" @default.
• W1972912578 modified "2023-10-01" @default.
• W1972912578 title "Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial" @default.
• W1972912578 cites W1854708637 @default.
• W1972912578 cites W1893347245 @default.
• W1972912578 cites W1976156924 @default.
• W1972912578 cites W1980725734 @default.
• W1972912578 cites W1995955591 @default.
• W1972912578 cites W2004494623 @default.
• W1972912578 cites W2004909463 @default.
• W1972912578 cites W2010881564 @default.
• W1972912578 cites W2042884540 @default.
• W1972912578 cites W2080439368 @default.
• W1972912578 cites W2086409166 @default.
• W1972912578 cites W2109823414 @default.
• W1972912578 cites W2110534364 @default.
• W1972912578 cites W2115735904 @default.
• W1972912578 cites W2120292596 @default.
• W1972912578 cites W2123098020 @default.
• W1972912578 cites W2123526148 @default.
• W1972912578 cites W2126937887 @default.
• W1972912578 cites W2139248078 @default.
• W1972912578 cites W2148643283 @default.
• W1972912578 cites W2151063703 @default.
• W1972912578 cites W2165088640 @default.
• W1972912578 cites W2165542862 @default.
• W1972912578 cites W2167123965 @default.
• W1972912578 cites W2167331614 @default.
• W1972912578 doi "https://doi.org/10.1016/s1470-2045(13)70184-0" @default.
• W1972912578 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23742877" @default.
• W1972912578 hasPublicationYear "2013" @default.
• W1972912578 type Work @default.
• W1972912578 sameAs 1972912578 @default.
• W1972912578 citedByCount "246" @default.
• W1972912578 countsByYear W19729125782013 @default.
• W1972912578 countsByYear W19729125782014 @default.
• W1972912578 countsByYear W19729125782015 @default.
• W1972912578 countsByYear W19729125782016 @default.
• W1972912578 countsByYear W19729125782017 @default.
• W1972912578 countsByYear W19729125782018 @default.
• W1972912578 countsByYear W19729125782019 @default.
• W1972912578 countsByYear W19729125782020 @default.
• W1972912578 countsByYear W19729125782021 @default.
• W1972912578 countsByYear W19729125782022 @default.
• W1972912578 countsByYear W19729125782023 @default.
• W1972912578 crossrefType "journal-article" @default.
• W1972912578 hasAuthorship W1972912578A5001456598 @default.
• W1972912578 hasAuthorship W1972912578A5007779528 @default.
• W1972912578 hasAuthorship W1972912578A5008067367 @default.
• W1972912578 hasAuthorship W1972912578A5013626155 @default.
• W1972912578 hasAuthorship W1972912578A5018358609 @default.
• W1972912578 hasAuthorship W1972912578A5028324203 @default.
• W1972912578 hasAuthorship W1972912578A5028926236 @default.
• W1972912578 hasAuthorship W1972912578A5034896538 @default.
• W1972912578 hasAuthorship W1972912578A5041215843 @default.
• W1972912578 hasAuthorship W1972912578A5046813012 @default.
• W1972912578 hasAuthorship W1972912578A5056263585 @default.
• W1972912578 hasAuthorship W1972912578A5064387281 @default.
• W1972912578 hasAuthorship W1972912578A5067036952 @default.
• W1972912578 hasAuthorship W1972912578A5072043188 @default.
• W1972912578 hasAuthorship W1972912578A5073295040 @default.
• W1972912578 hasAuthorship W1972912578A5076098983 @default.
• W1972912578 hasAuthorship W1972912578A5078851457 @default.
• W1972912578 hasAuthorship W1972912578A5080433169 @default.
• W1972912578 hasAuthorship W1972912578A5083604333 @default.
• W1972912578 hasAuthorship W1972912578A5086158535 @default.
• W1972912578 hasAuthorship W1972912578A5089060647 @default.
• W1972912578 hasConcept C121608353 @default.
• W1972912578 hasConcept C126322002 @default.
• W1972912578 hasConcept C126894567 @default.
• W1972912578 hasConcept C141071460 @default.
• W1972912578 hasConcept C142724271 @default.
• W1972912578 hasConcept C143998085 @default.
• W1972912578 hasConcept C168563851 @default.
• W1972912578 hasConcept C203092338 @default.

• next